G1 Therapeutics (GTHX) Stock Forecast, Price Target & Predictions
GTHX Stock Forecast
G1 Therapeutics stock forecast is as follows: an average price target of $4.50 (represents a -37.06% downside from GTHX’s last price of $7.15) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
GTHX Price Target
GTHX Analyst Ratings
Buy
G1 Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 25, 2024 | Gil Blum | Needham | $6.00 | $2.22 | 170.27% | -16.08% |
Jun 25, 2024 | Edward White | H.C. Wainwright | $3.00 | $2.22 | 35.14% | -58.04% |
G1 Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $4.50 |
Last Closing Price | $7.15 | $7.15 | $7.15 |
Upside/Downside | -100.00% | -100.00% | -37.06% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 07, 2024 | Raymond James | Market Perform | Downgrade | |
Aug 07, 2024 | Wedbush | Buy | Neutral | Downgrade |
Aug 07, 2024 | Needham | Buy | Hold | Downgrade |
Aug 07, 2024 | Rodman & Renshaw | Neutral | Downgrade | |
Jun 25, 2024 | Evercore ISI | Outperform | Upgrade | |
Jun 25, 2024 | Wells Fargo | Overweight | Upgrade | |
Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
Jun 13, 2024 | Needham | Buy | Buy | Hold |
Jun 13, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
Apr 12, 2024 | Wedbush | Buy | Buy | Hold |
Feb 28, 2024 | Wedbush | Buy | Buy | Hold |
Feb 28, 2024 | Needham | Underperform | Underperform | Hold |
Feb 13, 2024 | Needham | Buy | Buy | Hold |
Jan 03, 2023 | Needham | Buy | Buy | Hold |
G1 Therapeutics Financial Forecast
G1 Therapeutics Revenue Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.87M | $12.30M | $42.39M | $12.95M | $10.25M | $23.58M | $10.57M | $6.90M | $5.80M | $4.86M | $6.60M | $14.22M | $16.55M | $26.60M |
Avg Forecast | $25.50M | $24.43M | $23.33M | $22.23M | $21.09M | $19.94M | $18.79M | $17.65M | $25.71M | $23.81M | $22.07M | $20.43M | $19.54M | $17.96M | $16.26M | $15.21M | $13.08M | $14.24M | $28.95M | $11.17M | $9.66M | $23.33M | $9.14M | $6.37M | $5.71M | $4.78M | $2.77M | $775.00K | $4.64M | $28.57M |
High Forecast | $25.50M | $24.43M | $23.33M | $22.23M | $21.09M | $19.94M | $18.79M | $17.65M | $25.71M | $23.81M | $22.07M | $20.43M | $19.54M | $18.63M | $16.26M | $15.21M | $14.60M | $14.24M | $28.95M | $11.17M | $9.66M | $23.33M | $9.14M | $6.37M | $5.71M | $4.78M | $2.77M | $775.00K | $4.64M | $28.57M |
Low Forecast | $25.50M | $24.43M | $23.33M | $22.23M | $21.09M | $19.94M | $18.79M | $17.65M | $25.71M | $23.81M | $22.07M | $20.43M | $19.54M | $16.90M | $16.26M | $15.21M | $12.34M | $14.24M | $28.95M | $11.17M | $9.66M | $23.33M | $9.14M | $6.37M | $5.71M | $4.78M | $2.77M | $775.00K | $4.64M | $28.57M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14% | 0.86% | 1.46% | 1.16% | 1.06% | 1.01% | 1.16% | 1.08% | 1.01% | 1.02% | 2.38% | 18.35% | 3.56% | 0.93% |
Forecast
G1 Therapeutics EBITDA Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.20M | $-16.37M | $11.52M | $-24.51M | $-30.04M | $-21.15M | $-36.90M | $-46.81M | $-37.60M | $-41.10M | $-38.16M | $-25.44M | $-23.99M | $-9.84M |
Avg Forecast | $-12.61M | $-12.08M | $-11.54M | $-10.99M | $-10.43M | $-9.86M | $-9.29M | $-8.73M | $-12.71M | $-11.78M | $-10.91M | $-10.10M | $-9.66M | $-8.88M | $-8.04M | $-46.13M | $-6.47M | $-7.04M | $-14.32M | $-41.94M | $-44.98M | $-11.54M | $-4.52M | $-38.13M | $-2.83M | $-2.36M | $-1.37M | $-35.42M | $-2.30M | $-14.13M |
High Forecast | $-12.61M | $-12.08M | $-11.54M | $-10.99M | $-10.43M | $-9.86M | $-9.29M | $-8.73M | $-12.71M | $-11.78M | $-10.91M | $-10.10M | $-9.66M | $-8.36M | $-8.04M | $-36.91M | $-6.10M | $-7.04M | $-14.32M | $-33.55M | $-35.98M | $-11.54M | $-4.52M | $-30.50M | $-2.83M | $-2.36M | $-1.37M | $-28.34M | $-2.30M | $-14.13M |
Low Forecast | $-12.61M | $-12.08M | $-11.54M | $-10.99M | $-10.43M | $-9.86M | $-9.29M | $-8.73M | $-12.71M | $-11.78M | $-10.91M | $-10.10M | $-9.66M | $-9.21M | $-8.04M | $-55.36M | $-7.22M | $-7.04M | $-14.32M | $-50.33M | $-53.97M | $-11.54M | $-4.52M | $-45.75M | $-2.83M | $-2.36M | $-1.37M | $-42.50M | $-2.30M | $-14.13M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.89% | 2.32% | -0.80% | 0.58% | 0.67% | 1.83% | 8.17% | 1.23% | 13.30% | 17.38% | 27.81% | 0.72% | 10.45% | 0.70% |
Forecast
G1 Therapeutics Net Income Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.94M | $-18.20M | $8.71M | $-32.53M | $-33.65M | $-25.27M | $-41.93M | $-51.60M | $-40.02M | $-42.47M | $-39.42M | $-26.44M | $-25.35M | $-11.67M |
Avg Forecast | $5.79M | $5.11M | $4.42M | $3.72M | $2.49M | $1.76M | $1.03M | $325.35K | $5.51M | $3.94M | $2.89M | $-524.75K | $-2.55M | $-4.48M | $-8.66M | $-48.48M | $-14.58M | $-17.88M | $-11.46M | $-44.07M | $-47.87M | $-33.63M | $-53.46M | $-40.06M | $-54.28M | $-53.46M | $-51.21M | $-36.82M | $-47.18M | $-16.00M |
High Forecast | $5.79M | $5.11M | $4.42M | $3.72M | $2.49M | $1.76M | $1.03M | $325.35K | $5.51M | $3.94M | $2.89M | $-524.75K | $-2.55M | $-1.87M | $-8.66M | $-38.78M | $-11.88M | $-17.88M | $-11.46M | $-35.26M | $-38.29M | $-33.63M | $-53.46M | $-32.05M | $-54.28M | $-53.46M | $-51.21M | $-29.46M | $-47.18M | $-16.00M |
Low Forecast | $5.79M | $5.11M | $4.42M | $3.72M | $2.49M | $1.76M | $1.03M | $325.35K | $5.51M | $3.94M | $2.89M | $-524.75K | $-2.55M | $-6.35M | $-8.66M | $-58.17M | $-15.66M | $-17.88M | $-11.46M | $-52.88M | $-57.44M | $-33.63M | $-53.46M | $-48.08M | $-54.28M | $-53.46M | $-51.21M | $-44.19M | $-47.18M | $-16.00M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 1.02% | -0.76% | 0.74% | 0.70% | 0.75% | 0.78% | 1.29% | 0.74% | 0.79% | 0.77% | 0.72% | 0.54% | 0.73% |
Forecast
G1 Therapeutics SG&A Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $15.17M | $16.78M | $17.43M | $21.75M | $23.56M | $24.43M | $25.72M | $26.71M | $23.22M | $24.27M | $25.24M | $22.97M | $24.26M | $18.41M |
Avg Forecast | $42.70M | $40.91M | $39.07M | $37.22M | $35.31M | $33.39M | $31.46M | $29.56M | $43.04M | $39.87M | $36.95M | $34.20M | $32.72M | $30.07M | $27.22M | $25.47M | $21.91M | $23.84M | $48.47M | $18.71M | $16.18M | $39.06M | $15.30M | $10.67M | $9.57M | $8.00M | $4.65M | $1.30M | $7.77M | $47.84M |
High Forecast | $42.70M | $40.91M | $39.07M | $37.22M | $35.31M | $33.39M | $31.46M | $29.56M | $43.04M | $39.87M | $36.95M | $34.20M | $32.72M | $31.19M | $27.22M | $25.47M | $24.45M | $23.84M | $48.47M | $18.71M | $16.18M | $39.06M | $15.30M | $10.67M | $9.57M | $8.00M | $4.65M | $1.30M | $7.77M | $47.84M |
Low Forecast | $42.70M | $40.91M | $39.07M | $37.22M | $35.31M | $33.39M | $31.46M | $29.56M | $43.04M | $39.87M | $36.95M | $34.20M | $32.72M | $28.29M | $27.22M | $25.47M | $20.66M | $23.84M | $48.47M | $18.71M | $16.18M | $39.06M | $15.30M | $10.67M | $9.57M | $8.00M | $4.65M | $1.30M | $7.77M | $47.84M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.70% | 0.36% | 1.16% | 1.46% | 0.63% | 1.68% | 2.50% | 2.43% | 3.03% | 5.43% | 17.70% | 3.12% | 0.38% |
Forecast
G1 Therapeutics EPS Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | - | $-0.63 | $-0.77 | $-0.59 | $-0.98 | $-1.21 | $-0.94 | $-1.00 | $-0.94 | $-0.65 | $-0.67 | $-0.31 |
Avg Forecast | $0.11 | $0.10 | $0.08 | $0.07 | $0.05 | $0.03 | $0.02 | $0.01 | $0.10 | $0.07 | $0.06 | $-0.01 | $-0.05 | $-0.09 | $-0.17 | $-0.20 | $-0.28 | $-0.34 | $-0.22 | $-0.64 | $-0.84 | $-0.64 | $-1.02 | $-0.98 | $-1.03 | $-1.02 | $-0.98 | $-1.07 | $-0.90 | $-0.30 |
High Forecast | $0.11 | $0.10 | $0.08 | $0.07 | $0.05 | $0.03 | $0.02 | $0.01 | $0.10 | $0.07 | $0.06 | $-0.01 | $-0.05 | $-0.04 | $-0.17 | $-0.20 | $-0.23 | $-0.34 | $-0.22 | $-0.64 | $-0.84 | $-0.64 | $-1.02 | $-0.98 | $-1.03 | $-1.02 | $-0.98 | $-1.07 | $-0.90 | $-0.30 |
Low Forecast | $0.11 | $0.10 | $0.08 | $0.07 | $0.05 | $0.03 | $0.02 | $0.01 | $0.10 | $0.07 | $0.06 | $-0.01 | $-0.05 | $-0.12 | $-0.17 | $-0.20 | $-0.30 | $-0.34 | $-0.22 | $-0.64 | $-0.84 | $-0.64 | $-1.02 | $-0.98 | $-1.03 | $-1.02 | $-0.98 | $-1.07 | $-0.90 | $-0.30 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | -0.00% | 0.98% | 0.91% | 0.92% | 0.96% | 1.23% | 0.91% | 0.98% | 0.96% | 0.61% | 0.75% | 1.02% |
Forecast
G1 Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ALLO | Allogene Therapeutics | $2.07 | $29.00 | 1300.97% | Buy |
XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
PDSB | PDS Bio | $1.96 | $9.00 | 359.18% | Buy |
SGMO | Sangamo Therapeutics | $2.82 | $12.00 | 325.53% | Buy |
HRTX | Heron Therapeutics | $1.65 | $7.00 | 324.24% | Buy |
SANA | Sana Bio | $1.91 | $8.00 | 318.85% | Buy |
LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
CHRS | Coherus BioSciences | $1.71 | $6.00 | 250.88% | Hold |
ANNX | Annexon | $4.88 | $14.00 | 186.89% | Buy |
FATE | Fate Therapeutics | $1.88 | $5.00 | 165.96% | Buy |
MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
MGNX | MacroGenics | $3.34 | $7.00 | 109.58% | Hold |
RCUS | Arcus Biosciences | $16.08 | $31.71 | 97.20% | Buy |
AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
CRBU | Caribou Biosciences | $1.94 | $3.00 | 54.64% | Buy |
AXSM | Axsome Therapeutics | $93.51 | $133.00 | 42.23% | Buy |
HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |
ATRA | Atara Biotherapeutics | $10.35 | $14.00 | 35.27% | Sell |
BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |